# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mary McLeod Bethune (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML043-SYN
- Date: 2026-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viola Harrington-Mbeki, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Diagnosis visit: lung function, FeNO and echocardiogram results with the pulmonology consultation. **S**

## History of present illness

Mrs. Bethune returns two weeks after her first visit. This morning she had spirometry before and after albuterol, a diffusion test and FeNO in the pulmonary function laboratory, and an echocardiogram, and she then saw Dr. Oyelowo-Brandt. Her symptoms are unchanged: she wakes with cough and a tight chest two or three nights a week and is breathless on one flight of stairs; she has used albuterol most days. Her home blood pressure readings over the week averaged 144/84. She has heartburn two or three evenings a week and a blocked nose most days. She asks plainly whether this is asthma, her heart or her weight. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Tests this morning | Spirometry with bronchodilator response, DLCO, FeNO and transthoracic echocardiogram |
| Home blood pressure | Average 144/84 over seven days |
| Her question | Is it asthma, her heart, or her weight? |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Night cough and chest tightness two or three nights a week; breathless on one flight; wheeze with colds and dust |
| Cardiovascular | Negative | No chest pain, orthopnea needing extra pillows, ankle swelling or palpitations |
| Ears, nose, mouth, and throat | Positive | Blocked nose, postnasal drip and reduced smell |
| Gastrointestinal | Positive | Heartburn two or three evenings a week; no trouble swallowing |
| Constitutional | Negative | No fever or weight loss; weight 87.6 kg |
| Psychiatric | Negative | Determined; no low mood |

6 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum **S**
- Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 146/86 mmHg; pulse 78 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 96% on room air; weight 87.6 kg; BMI 33 kg/m². All vital signs are synthetic.

FEV1 before bronchodilator: 1.3 L (low); FEV1 after bronchodilator: 1.57 L; FEV1 percent predicted before bronchodilator: 64% (low); FEV1/FVC before bronchodilator: 0.64 (low); FEV1/FVC after bronchodilator: 0.72; DLCO: 17.2 mL/min/mm[Hg]; FeNO: 46 [ppb] (high); Left ventricular ejection fraction: 62%; Total IgE: 210 [IU]/mL (high); Asthma Control Test: 14. All results are synthetic.

## Change since baseline

- Asthma Control Test: 13 at baseline, 14 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Dignified and composed; speaks in full sentences; weight 87.6 kg; blood pressure 146/86, pulse 78; oxygen saturation 96 percent |
| Eyes | Fundoscopy: mild arteriolar narrowing; no hemorrhages or exudates |
| Nose | Swollen, pale inferior turbinates; no polyps visible by anterior rhinoscopy |
| Respiratory | Scattered expiratory wheeze on forced expiration; no crackles |
| Cardiovascular | Regular rhythm; no murmur or gallop; jugular venous pressure not raised; no edema; foot pulses present |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma, confirmed, uncontrolled** (J45.40). Asthma confirmed: FEV1 rose 270 mL (21 percent) after albuterol, and the post-bronchodilator FEV1/FVC of 0.72 shows no persistent obstruction, so this is not COPD; DLCO is normal; FeNO 46 ppb and blood eosinophils of 0.42 show type 2 inflammation. The results were read with race-neutral equations: with older race-based equations her FEV1 would have looked closer to normal. Her asthma is uncontrolled (Asthma Control Test 14), and albuterol alone is the riskiest way to treat it. Dr. Oyelowo-Brandt and I agree on GINA track 1. **S**
   - Budesonide-formoterol 160/4.5 mcg: one inhalation twice daily and one as needed, up to 12 a day; albuterol stopped.
   - Inhaler technique taught and checked today.
   - Written asthma action plan with peak flow zones; peak flow meter given.
   - Pneumococcal vaccine today.
2. **Hypertensive heart disease without heart failure** (I11.9). Her breathlessness is not from heart failure: BNP 48, ejection fraction 62 percent, no fluid on the chest X-ray and a normal jugular venous pressure. But the echocardiogram and ECG show mild left ventricular hypertrophy from untreated high blood pressure (clinic 146/86, home 144/84), so her heart needs protecting. **S**
   - Amlodipine 5 mg daily; no beta-blocker because of asthma.
   - Lower-salt diet; home readings to continue.
   - Potassium and kidney function at the next visit.
3. **Hyperlipidemia** (E78.5). LDL 144 mg/dL with hypertension and prediabetes: 10-year ASCVD risk above 20 percent. **S**
   - Atorvastatin 20 mg daily.
   - Lipid panel in six weeks.
4. **Chronic nasal symptoms** (R09.81). Years of blockage, postnasal drip and reduced smell with swollen turbinates: chronic rhinosinusitis is likely and worsens asthma. **S**
   - Fluticasone nasal spray and saline.
   - Ear, nose and throat review with nasal endoscopy in four weeks.
5. **Gastro-esophageal reflux** (K21.9). Symptomatic reflux, treated for its own sake. **S**
   - Omeprazole 20 mg daily for eight weeks.
   - No food for three hours before bed; head of the bed raised.
6. **Obesity, class 1** (E66.811). Her breathlessness is from asthma, not her weight, and she was told so; she would like help to walk more. **S**
   - Dietitian visit as she wishes.
   - A walking plan once her breathing settles.
7. **Wheeze, cough and breathlessness** (R06.2). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Spirometry with bronchodilator response, read with race-neutral equations; DLCO | At diagnosis, before starting controller therapy | Completed today | FEV1 1.30 L (64 percent) to 1.57 L (+270 mL, +21 percent); FEV1/FVC 0.64 to 0.72; DLCO 17.2 (92 percent) |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor response (NAEPP, conditional) | Completed today | 46 ppb, raised |
| Laboratory | Blood eosinophils and total and specific IgE (phenotyping) | At diagnosis and at severe asthma assessment | Completed today | Eosinophils 0.42 two weeks ago; total IgE 210; house dust mite specific IgE positive; cat, dog, cockroach and mold negative |
| Imaging | Echocardiogram, with BNP and chest X-ray from the first visit | To exclude heart failure when breathlessness is unexplained; for stage 2 hypertension or LVH | Completed today | Ejection fraction 62 percent; mild concentric LVH; grade 1 diastolic dysfunction; BNP 48 two weeks ago |
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 14; night waking two or three times a week; albuterol most days |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Taught today with her new inhaler; demonstrated correctly |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Written plan with peak flow zones given |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | No oral corticosteroid course, emergency visit or admission in the past year |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Starting at step 3: low-dose budesonide-formoterol maintenance and reliever |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Never smoker; dust, colds, perfume and humid air; dust mite covers advised because she is sensitized |
| Examination | Comorbidities: rhinosinusitis, reflux, obesity, sleep apnea screen, mood | At diagnosis and yearly | Completed today | Nasal symptoms (ear, nose and throat referral), reflux (omeprazole), BMI 33.0; STOP-BANG 2 (low risk); PHQ-2 1 at the first visit |
| Self-management | Vaccinations | Yearly | Completed today | PCV20 today; influenza and COVID-19 vaccines due in the autumn; RSV due |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Not yet: treatment has only now started |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 146/86; home average 144/84 over seven days |
| Examination | Fundoscopic examination | Yearly in hypertension | Completed today | Mild arteriolar narrowing |
| Laboratory | Baseline hypertension tests: kidney function, potassium, glucose or A1c, lipids, urine albumin, TSH; ECG | At diagnosis, then yearly | Up to date | All drawn at the first visit: creatinine 0.92, potassium 4.1, A1c 5.9 percent, LDL 144, urine albumin-to-creatinine ratio 18, TSH 2.2; ECG with LVH by voltage |
| Self-management | Equity: race-neutral lung function interpretation and plain explanation | Every test | Completed today | Read with GLI Global equations; results explained to her in plain words |

## Goal progress

- A confirmed diagnosis within three weeks: spirometry with bronchodilator response, FeNO and an echocardiogram, with the pulmonology consultation. Outcome by 2026-03-23: Asthma confirmed by a 21 percent, 270 mL bronchodilator response and FeNO 46 ppb; heart failure excluded; hypertensive heart disease found, two weeks after the first visit. **S**
- Asthma Control Test 20 or more, no night waking, and travel to Washington without breathlessness. In progress; target 2026-07-27. **S**
- Correct inhaler technique with her own inhaler at every visit, and a written asthma action plan she can use. In progress; target 2026-05-04. **S**
- Blood pressure below 130/80 at home and in clinic. In progress; target 2026-07-27. **S**
- No exacerbation needing oral corticosteroids. In progress; target 2026-07-27. **S**

## Medication changes

- Stopped: Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) **S**
- Started: Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**
- Started: Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum **S**
- Started: Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray **S**
- Started: Amlodipine 5 mg oral tablet, one tablet daily **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Started: Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. J Am Coll Cardiol 2022;79(17):1757-1780 (PMID 35379504) (2022), American Heart Association, American College of Cardiology and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society

## Follow-up

- Six-week review. Ear, nose and throat in four weeks. Follow the action plan: two extra inhalations and a call to the clinic if in the yellow zone for more than a day; emergency care in the red zone. **S**
- Next scheduled visit 2026-05-04: six-week asthma review: control, inhaler technique and adherence, the ear, nose and throat result, blood pressure and reflux. **S**
